A UK longitudinal associations study revealed that hyperlipidemias and inflammation independently and together raise the risk of serious cardiovascular diseases (CVD). The risk is more closely tied to the actual blood levels of these markers than to the use or not of cholesterol-lowering medication. Data were from 322,922 participants (55.9% women) aged 38 to 73 years with a median follow-up of 13.7 years. Higher levels of LDL cholesterol and lipoprotein(a) [Lp(a)] were linked to a greater chance of major CVD events. Elevated levels of high-sensitivity C-reactive protein (hs-CRP), markers associated with inflammation, also increased risk. Even among those taking cholesterol-lowering drugs, higher levels of these markers were associated with increased CVD risk. Individuals with high levels of all three markers—LDL cholesterol, Lp(a), and hs-CRP—faced a significantly higher CVD risk compared to those with lower levels. This study underscores the importance of monitoring and managing the markers to reduce the CVD risk. Source: https://academic.oup.com/eurheartj/
The American Cancer Society (ACS) concludes that the benefits of PSA-based screening for prostate cancer…
Proton pump inhibitor (PPI) use was modestly associated with incident dementia in older adults (pooled…
Extended follow-up of three major trials consistently shows that an initial invasive strategy does not…
Escitalopram, duloxetine, and agomelatine achieved higher sustained response rates than fluoxetine, while escitalopram and duloxetine…
Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…
In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…
This website uses cookies.